All In Biotech

Drug Trial Radar · NCT06106308

Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-line Treatment of Metastatic Colorectal Cancer in Patients With a KRAS or NRAS Mutation

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

110

Actual

Start

Feb 27, 2024

Primary completion

Apr 16, 2027

Study completion Apr 16, 2027

Sponsor

Lead sponsor
Cardiff OncologyIndustry
Sponsor type
Industry
Collaborators
Pfizer
First posted
Oct 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess 2 different doses of onvansertib to select the lowest dose that is maximally effective, and to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of onvansertib in combination with FOLFIRI + bevacizumab or FOLFOX + bevacizumab in patients with KRAS or NRAS-mutated metastatic colorectal cancer (CRC) in the first-line setting.

Conditions

  • Metastatic Colorectal Cancer
  • CRC
  • KRAS/NRAS Mutation

Interventions

  • OnvansertibDrug

    Oral capsule

  • FOLFIRIDrug

    FOLFIRI (irinotecan + fluorouracil \[5-FU\] + leucovorin) as intravenous (IV) infusion

  • BevacizumabDrug

    IV Infusion

  • FOLFOXDrug

    FOLFOX (leucovorin + fluorouracil \[5-FU\] + oxaliplatin) as intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR)Time frame: Up to approximately 1 year

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic - Arizona

    Phoenix, Arizona

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • St. Bernards Medical Center

    Jonesboro, Arkansas

  • Highlands Oncology Group

    Springdale, Arkansas

  • Pacific Cancer Medical Center

    Anaheim, California

  • Comprehensive Blood and Cancer Center - Bakersfield

    Bakersfield, California

  • Orange Coast Memorial Medical Center

    Fountain Valley, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Norris Comprehensive Cancer Center

    Los Angeles, California

  • UCLA Department of Medicine-Hematology/Oncology

    Los Angeles, California

  • Sharp Memorial Hospital

    San Diego, California

  • Torrance Memorial Physician Network - Cancer Care and Infusion Center

    Torrance, California

  • PIH Health

    Whittier, California

  • Memorial Cancer Institute

    Hollywood, Florida

  • Mayo Clinic - Florida

    Jacksonville, Florida

  • Cleveland Clinic Martin Health

    Stuart, Florida

  • Kaiser Permanente

    Honolulu, Hawaii

  • Fort Wayne Medical Oncology and Hematology

    Fort Wayne, Indiana

  • The University of Kansas Cancer Center - Westwood

    Westwood, Kansas

  • Cancer Center of Kansas

    Wichita, Kansas

  • Cancer & Hematology Centers of Western Michigan - Lemmen-Holton Cancer Pavilion

    Grand Rapids, Michigan

  • Mayo Clinic Cancer Center

    Rochester, Minnesota

  • Saint Luke's Hospital

    Kansas City, Missouri

  • Washington University School of Medicine Center for Advanced Medicine

    St Louis, Missouri

  • CCCN

    Las Vegas, Nevada

  • Manhattan Hematology Oncology (MHO) Research Foundation, Inc.

    New York, New York

  • Trihealth Kenwood

    Cincinnati, Ohio

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Lehigh Valley Health Network

    Allentown, Pennsylvania

  • West Cancer Clinic

    Germantown, Tennessee

  • Oncology Consultants, PA

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Utah Cancer Specialists

    Salt Lake City, Utah

  • University of Virginia

    Charlottesville, Virginia

  • Inova Schar Cancer Institute

    Fairfax, Virginia

  • VCU Massey Cancer Center

    Richmond, Virginia

  • Virginia Mason Medical Center

    Seattle, Washington

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.